Company Encyclopedia
View More
name
Opthea
OPT.US
Opthea Limited, a clinical-stage biopharmaceutical company, researches and develops therapeutic products based on targeting vascular endothelial growth factors (VEGF) C, D and R3 in Australia and the United States. The company’s pipeline includes Sozinibercept, which is in phase 3 to treat wet age-related macular degeneration (Wet AMD), as well as in phase 2 to treat diabetic macular edema (DME). It serves the biotechnology and healthcare industries. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015.
1.945 T
OPT.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
D
BiotechnologyIndustry
Industry Ranking356/394
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE117.59%A
    • Profit Margin-111500.68%E
    • Gross Margin100.00%A
  • Growth ScoreE
    • Revenue YoY-44.27%E
    • Net Profit YoY26.09%B
    • Total Assets YoY-69.91%E
    • Net Assets YoY-165.23%E
  • Cash ScoreD
    • Cash Flow Margin-0.09%D
    • OCF YoY-44.27%E
  • Operating ScoreE
    • Turnover0E
  • Debt ScoreE
    • Gearing Ratio454.00%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Opthea Limited held its Annual General Meeting

    Opthea Limited held its Annual General Meeting on November 11, 2025, where shareholders approved the re-election of Dr. Jeremy Levin and Ms. Kathy Connell as directors. Additionally, proposals for issuing options to Mr. Lawrence Gozlan and Ms. Kathy Connell under the NED Plan, as well as options to Dr. Jeremy Levin under the LTIP, were also approved.

    Reuters·
    US
    OPT
    0.00%
    US
    OPTEY
    +13.21%
    Reuters·
    US
    OPT
    0.00%
    US
    OPTEY
    +13.21%

    Opthea to Delist from Nasdaq, Focuses on ASX and Australian Market

    Opthea Limited (AU:OPT) has announced its voluntary delisting from the Nasdaq Stock Market, while retaining its listing on the Australian Securities Exchange (ASX). This decision aims to streamline operations and reduce costs, focusing on the Australian market to enhance shareholder value. The company will continue its American Depositary Receipt program for U.S. investors in the OTC market. The latest analyst rating for Opthea stock is a Sell, with a price target of A$0.05. Current market cap stands at A$738.8M.

    Tip Ranks·
    US
    OPT
    0.00%
    US
    OPTEY
    +13.21%
    Tip Ranks·
    US
    OPT
    0.00%
    US
    OPTEY
    +13.21%

    Opthea Appoints Hamish George As CFO

    Opthea Ltd. has appointed Hamish George as Chief Financial Officer, effective immediately. Additionally, Stephanie Vipond from Bio101 will take over as Joint Company Secretary, replacing Karen Adams. Both will manage communications between the company and ASX. Shares are currently trading at $3.41 on the Nasdaq.

    rttnews·
    US
    OPT
    0.00%
    US
    OPTEY
    +13.21%
    rttnews·
    US
    OPT
    0.00%
    US
    OPTEY
    +13.21%

    Opthea (NASDAQ:OPT) Trading 7.2% Higher - Here's What Happened

    Opthea Limited (NASDAQ:OPT) shares rose 7.2% to $3.41 on Friday, up from a previous close of $3.18. Analyst ratings show one Strong Buy, four Hold, and two Sell ratings, with a consensus target price of $1.33. Institutional investors own 55.95% of the stock, with significant increases in holdings from several firms. Opthea focuses on developing therapies for eye diseases in Australia, leveraging its intellectual property on Vascular Endothelial Growth Factors (VEGF).

    Market Beat·
    US
    OPT
    0.00%
    US
    OPTEY
    +13.21%
    Market Beat·
    US
    OPT
    0.00%
    US
    OPTEY
    +13.21%

    Opthea Limited Schedules Virtual Annual General Meeting for November 2025

    Opthea Limited has scheduled its virtual Annual General Meeting for November 11, 2025. Key agenda items include the re-election of directors and the adoption of the remuneration report. The latest analyst rating for OPT stock is a Hold with a $1.00 price target, while Spark's AI Analyst rates it as Underperform due to financial challenges. The stock shows a bearish trend, with unfavorable valuation metrics and a high beta, indicating a need for strategic improvements. Opthea focuses on developing therapies for eye diseases, with a current market cap of $485.2M.

    Tip Ranks·
    US
    OPT
    0.00%
    US
    OPTEY
    +13.21%
    Tip Ranks·
    US
    OPT
    0.00%
    US
    OPTEY
    +13.21%
    © 2025 Longbridge｜Disclaimer